ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Outcomes of left atrial appendage closure in patients with prior mitral valve interventions.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on left atrial appendage closure (LAAC) in valvular patients remain limited. This study aimed to evaluate procedural safety and outcomes of LAAC in patients with and without prior mitral valve interventions (PMVI).
methodsPatients who underwent transcatheter LAAC between 2016 and 2023 across high-volume centers in Europe and North America were included. Patients were stratified according to the presence or absence of PMVI (surgical or transcatheter). The primary endpoint was a composite of all-cause mortality and ischemic events (ischemic stroke or systemic embolism) at 2 years.
resultsAmong 1,213 consecutive patients, 142 had PMVI. Patients with PMVI had higher rates of chronic heart failure, permanent AF, and lower left ventricular ejection fraction. Disc-lobe devices and combined procedures were more frequently used in the PMVI group. Procedural success was very high in both groups (99.3% in PMVI vs. 99.4%, p = 0.83). Device-related thrombus (DRT) occurred in 6.8% of patients, with no difference between groups (7.0% in PMVI vs. 6.8%, p = 0.92). The cumulative incidence of all-cause mortality or ischemic stroke/systemic embolism at 2 years was similar between groups (21.3% vs. 21.8%, HR 1.14 [95% CI 0.76-1.72], p = 0.53). However, no ischemic stroke events were observed among patients with PMVI (0% vs. 4.6%, p = 0.012). PMVI was independently associated with a higher risk of all-cause mortality at maximum follow-up (adjusted OR 1.76, 95% CI 1.20-2.60; p = 0.004).
conclusionLAAC appears feasible and safe in patients with a history of PMVI. Despite a higher baseline risk and a higher adjusted risk of all-cause mortality, rates of ischemic stroke and thromboembolic complications remained low after LAAC.
Indexed as
Identifiers
42545494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.